T he neonatal Fc receptor (FcRn) was originally isolated from the intestinal epithelium of neonatal rats and shown to mediate uptake of IgG derived from the mother's milk 1, 2 , thereby its name. However, a large body of evidence has shown that FcRn is not restricted to neonatal life but is expressed in a variety of tissues and cell types at all stages of life, as reviewed elsewhere 3, 4 . A diverse set of FcRn functions at different body sites have just begun to emerge. The most studied function is its role as a serum half-life regulator, as FcRn extends the serum persistence of IgG subclass antibodies and albumin to three weeks in humans [5] [6] [7] [8] [9] . Responsible is a cellular recycling mechanism that takes place in hematopoietic cells as well as endothelial cells lining blood vessels [10] [11] [12] . Within these cells, FcRn resides predominantly in acidified intracellular compartments where the low pH triggers binding of IgG and albumin to FcRn. This results in recycling of the complex back to the cell surface where exposure to the near neutral pH of the blood triggers release of the ligands from the receptor. The strict pH dependence of both interactions is fundamental for efficient recycling and thereby rescue from intracellular degradation.
In addition, FcRn transports IgG across different cellular barriers such the mucosal epithelium lining the intestine and the alveolar surfaces 13, 14 , and delivers IgG from the mother to the fetus via the placenta 15, 16 . The mechanism secures passive immunity of the newborn in a critical phase of early life. Furthermore, FcRn has been found to collaborate with the classical Fcc receptors expressed on immune cells in orchestration of uptake and processing of IgG-immune complexes, leading to antigen presentation and induction of T cell immunity 17, 18 . FcRn is a major histocompatibility complex (MHC) class I-related transmembrane trafficking receptor. It is a heterodimer with an evolutionally distinct heavy chain (HC) non-covalently associated with the b2-microglobulin light chain, which is common to most MHC class I family molecules 19, 20 . For all functions, pH-dependent binding to both ligands is fundamental, binding at acidic pH (6-6.5), and releases or no binding at neutral pH (7.4) 6, 19, 21 . IgG and albumin bind to separate binding sites on the FcRn HC in a non-cooperative fashion [21] [22] [23] [24] . X-ray crystallography and site-directed mutagenesis studies have revealed that histidine residues located at the C H 2-C H 3 elbow region of the IgG Fc (H310 and H435) are central for IgG binding 6, 19, 20 . At acidic pH their imidazole groups are positively charged and facilitate interaction with negatively charged residues located within the a 2 -domain of the receptor (E115 and E116 in humans, and E117 and E118 in rats), while at pH 7.4, the imidazole rings are neutral and thereby do not interact with FcRn. Similarly, three histidines within the C-terminal domain III of albumin (H464, H510 and H535) are engaged in binding to FcRn at a site opposite the IgG binding site 21 . In addition, H166 of the a 2 -domain of FcRn stabilizes a flexible surface-exposed loop within the a1-domain (residue 51-60) of hFcRn in a pH-dependent way 21, 22 . Thus, histidines are crucial for pH-dependent binding of FcRn to both ligands.
FcRn function is critical for controlling and optimizing pharmacokinetics and bioavailability of monoclonal IgG and IgG Fc-fused therapeutics as well as albumin-fused or conjugated therapeutics 25, 26 . Still, major questions regarding the cellular distribution of FcRn and how it transports both its ligands across or within different cell types remain to be addressed at a molecular and cellular level. To study the biology of FcRn in health and disease, methods to detect its presence and transport are needed, and in particular, detection reagents other than anti-FcRn IgG antibodies, which may interfere with FcRn function, are preferred.
This report describes the generation of FcRn probes from a combinatorial library of light chain devoided IgG variable regions obtained from a llama immunized with recombinant soluble hFcRn using phage display. Such variable HC only (VHH) antibodies are naturally occurring in Camelidae and their entire binding unit is termed NanobodiesH (Nb) 27 . We identified Nbs with specificity for folded hFcRn, which do not interfere with pH-dependent binding to IgG or albumin. Importantly, Nb binding to hFcRn was not affected by pH and did not affect FcRn-mediated transcellular transport of IgG. The Nbs could also be directly conjugated to an enzyme or fluorochromes without losing FcRn binding activity. Thus, the Nbs selected are attractive tools for studying FcRn biology. Results Immunization of llamas. One llama (L. glama) was immunized with purified soluble recombinant hFcRn over a period of 6 weeks. The induction of llama IgG antibodies directed towards hFcRn was demonstrated by ELISA on sera collected before and 21 days after immunization, ( Figure 1A ). Subsequently, a cDNA library encoding the in vivo matured variable domain repertoire of HC only antibodies (VHH) were prepared from isolated PBLs and draining lymph nodes biopsies, followed by cloning of the PCR-amplified fragments into a phage display library. The resulting library contained approximately 7 2 8 3 10 8 independent clones.
Phage display selection. To select for hFcRn-specific phages, the phage display library was panned on recombinant hFcRn coated by ELISA wells at pH 5.1 followed by trypsin elution. After two rounds of selection, individual phages were isolated and screened for binding to hFcRn at pH 6.0 and pH 7.1 in ELISA. Phage particles were identified that bound hFcRn at both pH conditions. Binding of four of the selected phage clones is shown in Figure 1B , where the strongest binding response was seen for a phage clone Nb218-C5 followed by Nb216-E6, Nb218-H4 and Nb218-A5. All the clones showed a slightly better response at acidic than at neutral pH.
Binding properties of selected anti-hFcRn Nanobodies. The variable domains from four isolated phage clones were sub-cloned into an expression vector designed for production of recombinant Nbs in E. coli. The cDNAs were cloned upstream of a C-terminal cMyc tag followed by a His 6 tag. The purified Nbs was analyzed on SDS-PAGE gels and seen as distinct bands of approximately 15-17 kDa, corresponding to their expected molecular weights. A representative SDS-PAGE gel of the purified Nb218-H4 and a control variant with irrelevant specificity (Nb203-G8) is shown in Figure 2A .
To verify that the produced monomeric Nbs bound hFcRn, ELISA was performed with equal amounts of the Nbs captured on an anti cMyc mouse IgG1 antibody coated in wells (mIgG1 does not bind hFcRn). Receptor binding was confirmed by adding GST-tagged hFcRn followed by visualization using an HRP-conjugated anti-GST antibody. All four Nbs were shown to bind the receptor at both pH conditions with a slightly better binding at pH 6.0 ( Figure 2B ). Nb218-C5, Nb216-E6 and Nb218-H4 bound equally well, followed by Nb218-A5, while the negative Nb control did not bind.
FcRn is a heterodimer consisting of a HC that is folded up on b2-microglobulin, which is shared between all MHC class I and related molecules. Thus, to be used as cellular detection probe for hFcRn, the selected Nbs must bind specifically to the HC only. To avoid selection of anti-b2-microglobulin clones, selection steps were performed in the presence of human b2-microglobulin in solution. To confirm that the generated Nbs bound specifically to the HC, we also screened for binding towards human b2-microglobulin by ELISA, and conclusively demonstrated that all four Nbs bound specifically to the hFcRn HC ( Figure 2C ). Furthermore, we confirmed by SPR that the anti-FcRn Nbs bound hFcRn at both pH conditions (Supplemental Fig. S1 ).
Selected Nbs bind hFcRn independently of the ligands. To investigate whether or not IgG and albumin bound to hFcRn affected binding of the Nbs at acidic pH, we used SPR with immobilized human IgG1 and albumin on CM5 sensor chips and injected recombinant hFcRn alone or in complex with anti-FcRn Nbs at pH 6.0. None of the Nbs interfered with binding of the ligands to hFcRn, as additive binding to immobilized ligands was observed for all four Nbs, while binding in the presence of Nb control was unaffected ( Figure 2D -E).
Monomeric and bivalent Nb218-H4. The binding affinity of monomeric Nb218-H4 was determined by SPR by injection of serial dilutions over immobilized hFcRn at pH 6.0 and pH 7.4. The resulting binding curves were either fitted to a steady state affinity binding model ( Figure 3A -B) or a simple 1:1 Langmuir binding model ( Figure 3C ). Both kinetic binding models gave rise to similar estimated KD values of roughly 20 3 10 29 M at pH 6.0, and a 2-fold weaker affinity at pH 7.4 (Table 1) .
To improve apparent affinity through avid binding, we constructed a dimeric form of Nb218-H4. Two units were genetically fused via a glycine-serine linker. The purified (Nb218-H4) 2 variant as well as a dimeric negative control Nb were shown to migrate with the expected molecular sizes on a SDS-PAGE gel ( Figure 2A ). Then, equimolar amounts of monomeric and dimeric Nb218-H4 were injected over immobilized hFcRn, which resulted in a considerably increased avidity of the dimer as demonstrated by a very slow dissociation phase compared with the monomer ( Figure 3D ).
Conjugation and visualization of hFcRn.
To validate the utility of these Nb as detection probes, we then tested FcRn binding of Nb218-H4 directly conjugated to an enzyme or fluorochrome. First, HRPconjugation to Nb218-H4 was shown not to disrupt binding to hFcRn, as the conjugate could be used as a sensitive detection probe in ELISA assays for pH-dependent binding of FcRn to IgG and albumin ( Figure 4A-B) . Next, we investigated whether Alexa488-conjugated (Nb218-H4) 2 could be used for visualization of cellularly expressed hFcRn. HeLa cells were transfected with plasmids encoding RFP-fused hFcRn and human b2-microglobulin, and the next day, cells were chased with Alexa488-conjugated (Nb218-H4) 2 or a bivalent Nb control. Only Alexa488-(Nb218-H4) 2 was shown to co-localize with hFcRn-RFP in intracellular compartments ( Figure 4C ). When Alexa647-conjugated human albumin was added in the presence of Alexa488-(Nb218-H4) 2 , RFP-hFcRn was shown to localize with both (Nb218-H4) 2 and albumin ( Figure 4D ).
Furthermore, HeLa cells transfected with a plasmid encoding only the RFP-fused hFcRn HC showed retention of the HC in the endoplasmatic reticulum, which is in agreement with previous findings demonstrating that proper folding of the FcRn HC is completely dependent on co-expression of b2-microglobulin 28 . Importantly, (Nb218-H4) 2 did not co-stain with RFP-hFcRn in cells transfected with the HC only ( Figure 4E ). Thus, anti-FcRn (Nb218-H4) 2 binds only to folded heterodimeric hFcRn. In addition, we confirmed that Alexa488-conjugated (Nb218-H4) 2 could be used to stain FcRn positive cells by flow cytometry (Supplemental Fig. S2 ).
FcRn-mediated transcytosis of IgG. Finally, we addressed whether the presence of Nb218-H4 would affect FcRn-mediated transcytosis of human IgG1 across a monolayer of T84, a polarized human epithelial cell line known to express endogenous hFcRn 29 . Cells were seeded in a Transwell system and grown to high electrical resistance before recombinantly produced human IgG1 antibodies with specificity for the hapten NIP, a WT variant and a triple mutant (I253A/H310A/H435A; IHH) with reduced FcRn binding, were added to the apical reservoirs. Samples were collected from the basolateral side at time 0 and 4 hours post addition to the apical side. The amounts of IgG1 variants transported across the cellular layers were quantified by ELISA, which demonstrated that IgG1-WT was transported more efficiently than the IHH triple mutant ( Figure 5 ). When the same experiment was performed in the presence of a 15-fold excess amount of Nb218-H4, no difference in transcytosis of WT IgG1 was detected ( Figure 5) . Thus, binding of Nb218-H4 to hFcRn does not interfere with transcellular transport of IgG.
Discussion
FcRn fulfills important functions in IgG-mediated immune surveillance and transport of albumin throughout the body. The increasing appreciation of the impact of FcRn in both homeostatic regulation of the two ligands and pathological conditions related to IgG-mediated autoimmunity has resulted in an intense interest from academia as well as biotech companies. Especially, engineering of FcRn binding and transport of IgG has resulted in development of therapeutic IgGs and IgG-derived Fc fusions with improved serum half-life 25, 26, [30] [31] [32] . Furthermore, FcRn blockers, such as peptides that bind tightly to the IgG binding site, inhibit FcRn binding and rescue of circulating IgG, resulting in reduced blood levels of IgG 33 . Beside half-life regulation, a large body of evidence has shown that FcRn is expressed in epithelial cells lining the mucosal surfaces where it mediates transport of IgG and IgG-containing immune complexes, which may result in induction of immunity or development of diseases such as colitis 12, 13, 34 . Furthermore, recent studies have demonstrated a central role of FcRn in processing of IgG-containing immune complexes in dendritic cells for subsequent presentation of antigenic peptides on both MHC class I and II 17, 18 . How these processes are regulated at molecular and cellular levels has not been studied in detail.
The overall goal of this study was to develop and characterize Nbs with specificity for the human form of FcRn. This was motivated by the need for reliable probes for studying the molecular and cellular biology of hFcRn. To this end, a llama was immunized with recombinant soluble hFcRn, followed by the construction of a VHH library and panning on soluble hFcRn. FcRn binds both its ligands strongly only at the acidic pH found within endosomal compartments. However, the selected Nbs bound hFcRn at acidic as well as at neutral pH, exemplified by Nb214-H8, which only showed a 2-fold difference in affinity between pH 6.0 and 7.4. This is important, as the probe will detect hFcRn at the relevant cellular conditions. None of the anti-FcRn Nbs selected was shown to interfere with pHdependent binding of IgG and albumin to the receptor, which is a prerequisite for the use of such Nbs as FcRn detection probes to address FcRn-mediated ligand binding and transport.
We explored the applications of the Nbs using in vitro binding assays such as ELISA and SPR and found that they could easily be used to detect hFcRn alone or bound to ligands. Also, conjugation of HRP to the minimal Nb214-H8 demonstrated retained ability to bind strongly to hFcRn. Thus, it can be used as a capture reagent or as a detection probe. This was also the case for a dimeric version of Nb214-H8. Furthermore, we conjugated (Nb214-H8) 2 to fluorochromes, and showed that it could be used as cellular tracker to examine FcRn expression and distribution without affecting ligand binding and transport. A notable feature of Nb214-H8 is that it only binds to fully folded hFcRn and as such it only stains hFcRn that has left the endoplasmic reticulum. Besides hFcRn, we have found that Nb218-H4 binds strongly to FcRn from rhesus monkey, weakly to FcRn from pig, and not at all to FcRn from mouse and rat (Supplemental Fig. S3 ).
In conclusion, we have developed Nbs with specificity for hFcRn. The identified minimal Nbs bind independently of IgG and albumin to hFcRn, and thus are ideally suited for detection and tracking of hFcRn.
Methods
Production of recombinant hFcRn. Vectors encoding truncated versions of the three ectodomains (a1-a3) of mouse, rat and human FcRn HC cDNAs genetically fused to a cDNA encoding the Schistosoma japonicum glutathione S-transferase (GST) have been described 24, 35, 36 . The vectors also contain a cDNA encoding human b 2 -microglobulin and the Epstein-Barr virus origin of replication (oriP). Similar, truncated forms of FcRn HC cDNAs from monkey and pig were synthesized by Genscript and subcloned into the vector system using the restriction sites XhoI and HindIII. All FcRn variants were produced in adherent human embryonic kidney 293E cells, and secreted receptors were purified using a GSTrap column as described 37 . An E. coli produced form of refolded hFcRn was produced and purified as previously described 36 .
Immunizations of llamas. Animal experiments were conducted with the approval of the Ethical committee of the Faculty of Veterinary Medicine (University of Ghent, Belgium, EC number is 2006/076, LA number is 1400088). The animal immunization protocol is based upon the guidelines available for Guanaco and Vicuña (llama species) as described in the Ministerial Decree of 05.03.1999 (for zoo animals) and the guidelines for farm animals used as laboratory animals described in Appendix A of the European convention for the protection of vertebrate animals used for experimental and other scientific purposes, from the European Treaty Series (ETS) 123. In addition, the animal facility was complied with the basic principles of animal care as specified by the Royal Decree 14/08/1986, Law on the Protection and Welfare of Animals (last amended 19/05/2010). This Decree aims to ensure that all species of animal are protected from harm and neglect and are provided with conditions that meet their welfare needs. One llama was immunized with 3 doses of 50-100 mg E. coli produced hFcRn 38 . Blood was collected 22 days after the last boost. Approximately 1 g of lymph nodes was collected 4 days after boost 6.
Phage library construction. PBLs were purified by a Ficoll-Paque density gradient centrifugation (Amersham Biosciences, Uppsala, Sweden) according to the manufacturer's instructions. Next, total RNA was extracted and transcribed into cDNA (Invitrogen superscript III kit). The generated cDNA was used for nested RT-PCR to amplify the Nbs encoding gene fragments as previously described 39 , and cloned into the phagemid pAX50. The size of the library after transformation of E. coli TG1 was determined as 7 2 8 3 10
8 CFUs. 96-100% of the clones contained a correct size insert as evaluated by colony PCR on 24 randomly picked colonies using M13 reverse and a geneIII primers. Phages were prepared according to standard methods and stored at 4uC and/or in 20% glycerol at 220uC.
Phage display selections. Refolded hFcRn was used in selections performed at pH 5.1. FcRn (0-10 mg/ml) was immobilized on Maxisorp 96 well microtiter plates (Nunc) in PBS at pH 7.4 overnight at 4uC. After 2 hours blocking with 4% skimmed milk-PBS, the phages were added and incubated at 37uC in 2% skimmed milk-pH 5.1 CPA buffer (10 mM sodium citrate, 10 mM sodium phosphate, 10 mM sodium acetate, 115 mM NaCl, pH 5.1) or in 2% skimmed milk-PBS in the presence of human b2-microglobulin (12-100 mg/ml) (Sigma-Aldrich). After 2 hours, the plates were extensively washed with pH 5.1 CPA buffer20.05% Tween20 or with PBS-0.05% Tween20 and bound phages were eluted using trypsin (1 mg/ml) for 15 minutes at 37uC. The eluted phages were amplified in E. coli TG1 and subjected to a second, similar selection. Eluted phages were again rescued in TG1. Individual colonies were picked and grown in 96 well plates. Monoclonal phages were produced by addition of helper phages.
Phage binding ELISA. hFcRn or human b2-microglobulin (0.5 mg/ml) were immobilized on Maxisorp ELISA plates (Nunc) at 4uC over night, followed by 2 hours blocking using 4% skimmed milk-PBS. After washing with pH 5.1 or pH 7.4 CPA buffer, 10 ml of the different phages diluted in 100 ml of 2% skimmed milk/pH 5.1 or pH 7.4 CPA buffer and allowed to bind to the immobilized antigen. After 2 hours incubation and washing with pH 5.1 or pH 7.4 CPA buffer, 100 ml of a horse reddish peroxidase (HRP)-conjugated monoclonal-anti-M13 antibody (GE Healthcare, 1510000 dilutions) in 1% skimmed milk/pH 5.1 or pH 7.4 CPA buffer was added to the wells for 1 hour. Phage binding was detected by adding 100 ml of 3,39,5,59-Tetramethylbenzidine (TMB) substrate (Pierce). The reaction was stopped after 15 minutes and absorbance was measured at 450 nm using a TECAN Sunrise spectrophotometer (TECAN, Maennedorf, Switzerland). Binding specificity was determined based on OD values compared to controls wells having received an irrelevant phage clone or no phage.
Generation of bivalent Nanobodies. Bivalent Nb fusions consisting of two copies of the Nb218-H4 or a Nb with irrelevant specificity (Nb203-G8) linked via a 20 amino acid linker (repetitive (GGGGS) 4 sequence) were constructed by separate PCR reactions (one for the N-terminal and one for the C-terminal), using different sets of primers encompassing parts of the linker and restriction sites MfeI in the N-terminal, or BstEII in the C-terminal. The resulting PCR products were digested with the www.nature.com/scientificreports SCIENTIFIC REPORTS | 3 : 1118 | DOI: 10.1038/srep01118correspondent enzymes and sub-cloned into an expression vector containing C-terminal c-Myc and His 6 tags.
Nanobody production and purification. Exponentially growing E. coli cultures (50-1000 ml) were induced with 1 mM isopropyl-D-thiogalactopyranoside for 4 hours at 37uC. Bacterial periplasmic space was extracted by centrifugation, freeze/thaw of the pellet and re-suspension in PBS followed by final centrifugation. Nbs were purified from the supernatants i) using TALON beads (Clontech Laboratories, Mountain View, CA) according to the manufacturer recommendation, and dialyzing against PBS, or ii) by using His Trap TM FF chromatography columns (GE Healthcare), followed by gel filtration using a HiLoad 16/10 Superdex 75 prep grade column (GE Healthcare). Purity and concentration of the purified Nbs were determined by SDS-PAGE analysis.
Nanobody HRP conjugation. Purified Nbs were conjugated to HRP using the EZLink Plus Activated Peroxidase kit (Pierce). Conjugates were purified using a Sephadex-G75 column. 0.5 ml fractions were collected and size-separated by SDS-PAGE followed by Coomassie staining. The HRP activity of the fractions was determined by ELISA where Nb was captured by an immobilized anti c-Myc tag antibody (monoclonal, mIgG1; Serotec) and detection was carried out using TMB substrate.
Nanobody Alexa labeling. Purified Nbs were adjusted to pH 8.3 with 1/10 volume 1 M NaHCO 3 and directly labeled with amine-reactive AlexaFluor647 or with AlexaFluor488 (Invitrogen). A 10-fold M excess of dye over protein was used. Labeling reaction was quenched using 1/10 volume 1.5 M Tris-HCl. Desalting was performed on PD MiniTRap G25 spin columns (GE Healthcare). Human albumin (Sigma-Aldrich) was conjugated to Alexa647 using Alexa Fluor 647 Protein Labeling Kit (Invitrogen). The concentration of the conjugated proteins was estimated both spectrophotometrically (Nanodrop, Thermo Scientific) and by densitometry analyses of scanned Coomassie-stained SDS-PAGE.
FcRn binding ELISA. Wells were coated with 100 ml of an anti-Myc antibody (Serotec) at 1.0 mg/ml, and incubated overnight at 4uC. They were then blocked for 1 hour with 4% skimmed milk (Acumedia) and washed four times with PBS/0.005% Tween 20 (PBS/T) pH 7.4. Nb candidates (2 mg/ml) in 4% skimmed milk/PBS/T were added to the wells. After incubation for 1 hour, the wells were washed four times with PBS/T pH 7.4. GST-tagged hFcRn (0.5 mg/ml) pre-incubated with an HRPconjugated polyclonal anti-GST antibody from goat (155000; GE Healthcare) in 4% skimmed milk PBS/T pH 7.4 was added to each well and incubated for 1 hour. Following four washes with PBS/T pH 7.4, 100 ml of ABTS/H 2 O 2 (Sigma-Aldrich) was added and absorbance at 405 nm was measured using a TECAN Sunrise spectrophotometer (TECAN). The assay was repeated with PBS/T pH 6.0, and with serial dilutions of Nbs (0.016-4.0 mg/ml). To determine species cross-reactivity, the ELISA was performed using soluble GST-tagged forms of mouse, rat, pig, monkey FcRn. Alternatively, titrated amounts of IgG or human albumin were coated in wells followed by GST-tagged hFcRn and detection using HRP-conjugated Nb218-H4.
Human b2-microglobulin (Abcam) was coated (5 mg/ml) and incubated overnight at 4uC. Wells were then blocked in with 4% skimmed milk for 1 hour and washed four times with PBS/T pH 6.0. Nb candidates (2 mg/ml) were pre-incubated with an HRPconjugated anti c-Myc antibody (mIgG1, Serotec) in 4% skimmed milk/PBS/T and added to the wells. After incubation for 1 hour, the wells were washed four times with PBS/T pH 6.0. 100 ml of the substrate TMB (Calbiochem) was added to each well and the absorbance was measured at 620 nm using a TECAN Sunrise spectrophotometer (TECAN). An anti-human b2-microglobulin antibody (152000; Sigma-Aldrich) was included as a positive control and binding visualized using HRP-conjugated protein G (Calbiochem).
Detection of llama IgG antibodies directed towards hFcRn in pre-and postimmunization sera was done similarly, using mouse-anti-llama antibodies 40 followed by an HRP-conjugated rabbit anti-mouse antibody (Dako, DK).
SPR. SPR experiments were carried out using a Biacore 3000 instrument (GE Healthcare). Flow cells of CM5 sensor chips were coupled with hFcRn-GST (,800 RU), human IgG or human albumin (,1000 RU) using amine coupling chemistry as described by the manufacturer. The coupling was performed by injecting 10 mg/ml of the receptor in 10 mM sodium acetate pH 5.0 (GE healthcare). For all experiments, phosphate buffer (67 mM phosphate buffer, 0.15 M NaCl, 0.005% Tween 20) at pH 6.0 or pH 7.4, or HBS-EP buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20) at pH 7.4 (GE Healthcare) were used as running buffer and dilution buffer.
For competitive binding analyses, hFcRn was pre-incubated with the Nb candidates and injected over immobilized human IgG1 or albumin at pH 6.0. All injections were done using a constant flow rate of 10 ml/min at 25uC. For kinetic analysis, serial dilutions (500-15 nM) of monomeric Nb218-H4 were injected at a flow rate of 50 ml/ min at 25uC over immobilized hFcRn at pH 6.0 or pH 7.4. The resulting sensorgrams were analyzed using the BIAevaluation 4.1 software using Langmuir 151 binding model and the steady state affinity binding models to derive binding kinetics. In all experiments, data were zero adjusted and the reference cell subtracted.
Flow cytometry. The human monocytic cell line THP-1 (ATCC) was cultured in RPMI 1640 (BioWhittaker, Belgium) supplemented with 4 mM L-glutamine, 100 U/ml penicillin (Integro, The Netherlands), 0.1 mM nonessential amino acids and 10% foetal calf serum (FCS) (Integro). 1 3 10 6 cells were washed three times with PBS followed by centrifugation at 800 rpm, re-suspended and added to 96-well plates (Nunc). Cells were fixed with 3% paraformaldehyde (PFA) (Sigma-Aldrich) for 30 min, permeabilized with 0.1% saponin and then blocked with 2% bovine serum albumin (BSA)/PBS (Sigma-Aldrich) for 1 hour. Following three washes with PBS/ BSA, Alexa488 or Alexa647 conjugated (Nb218-H4) 2 or a bivalent control Nb (1 mg/ ml) diluted in PBS/BSA were added. Following 1 hour staining at 4uC, cells were again washed as described above and analyzed by flow cytometry.
Immunofluorescence and confocal laser scanning microscopy. HeLa cells were grown on coverslips to 70% confluence in complete DMEM and transfected with vectors encoding hFcRn-RFP and human b2-microglobulin or hFcRn-RFP alone, using FuGENE 6.0 transfection reagent according to the recommendations from the manufacturer (Roche). One day post transfection, cells were incubated with 2 mg/ml fluorescently conjugated (Nb218-H4) 2 (Alexa 488), an Nb control (Alexa 488), or human albumin (Alexa 647, all fluorochromes from Invitrogen) for 1 hour. Cells were then washed in PBS, fixed in 3% PFA and mounted onto object-glasses with Mowiol (Sigma-Aldrich). Confocal images were acquired on an Olympus FluoView 1000 microscope equipped with a PlanApo 0/1.10 oil objective (Olympus, Hamburg, Germany). Fluorochromes were exited with 488 nm Argon, 543 nm and 647 nm HeNe lasers. All image acquisition was done by sequential line scanning to eliminate bleed-through. Images were processed with ImageJ (NIH, USA) and assembled in Adobe Illustrator (Adobe systems Inc., CA, USA).
Transepithelial IgG transport. The human T84 cell line (ATCC) was maintained in DMEM and HAM s F-12 medium (151) supplied with 10% FCS (Intebro b.v.), 2.5 mM L-glutamine, 25 mg/ml streptomycin and 25 U/ml penicillin (all from BioWhittaker). 3 3 10 6 cells were seeded on Transwell filters with 0.4 mm pore size (Corning Costar, MA, USA) and transepithelial resistance was measured daily using MILLICELL-ERS volt-ohm meter (MILLIPORE). The cells were grown as monolayers for 4-6 days until the resistance reached 1000-1500 V/cm 2 . Growth medium were exchanged daily. Cells were then cultured in HBSS1 buffer for 1 hour before equal amounts (66 nM) of recombinant human IgG1-WT and IgG1 IHH (I253A/H310A/H435A) with specificity for 5-iodo-4-hydroxy-3-nitro-phenylacetyl (NIP) was added to individual apical reservoirs. At time 0 and 4 h post addition, samples were collected from the basolateral reservoirs, and the amounts of IgG present quantified by ELISA. The same assay was performed in the presence of 1 mM of the Nb218-H4 or an Nb with irrelevant specificity, both added to the apical side 20 minutes before the IgG antibodies were provided.
